Boston Scientific Corporation
BSX
$73.85
-$2.37-3.11%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.90% | 20.34% | 22.84% | 20.93% | 22.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.90% | 20.34% | 22.84% | 20.93% | 22.44% |
| Cost of Revenue | 9.42% | 16.55% | 29.09% | 20.34% | 27.37% |
| Gross Profit | 18.99% | 22.06% | 20.03% | 21.20% | 20.22% |
| SG&A Expenses | 13.77% | 11.46% | 18.67% | 17.08% | 16.90% |
| Depreciation & Amortization | 1.33% | 9.76% | 5.63% | 2.34% | 8.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.57% | 15.01% | 24.00% | 17.80% | 21.33% |
| Operating Income | 31.77% | 46.24% | 18.02% | 35.21% | 28.04% |
| Income Before Tax | 19.86% | 40.21% | 124.05% | 32.18% | 15.64% |
| Income Tax Expenses | 30.43% | -8.50% | 48.98% | 15.65% | 2,200.00% |
| Earnings from Continuing Operations | 19.43% | 60.98% | 146.89% | 36.03% | 11.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -50.00% | -- | 0.00% | 100.00% | 300.00% |
| Net Income | 18.94% | 60.98% | 145.99% | 36.16% | 11.88% |
| EBIT | 31.77% | 46.24% | 18.02% | 35.21% | 28.04% |
| EBITDA | 23.55% | 35.94% | 15.23% | 26.58% | 22.37% |
| EPS Basic | 18.24% | 59.97% | 144.44% | 35.36% | 11.23% |
| Normalized Basic EPS | 31.34% | 42.33% | 75.67% | 34.03% | 31.70% |
| EPS Diluted | 18.54% | 59.97% | 140.91% | 36.36% | 11.97% |
| Normalized Diluted EPS | 31.62% | 42.42% | 75.65% | 33.76% | 31.34% |
| Average Basic Shares Outstanding | 0.58% | 0.61% | 0.63% | 0.60% | 0.61% |
| Average Diluted Shares Outstanding | 0.38% | 0.54% | 0.63% | 0.77% | 0.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |